Finance

Lists
Why is LAB up 2.82%?
Dive Deeper
LAB:NASDAQ
Standard Biotools Inc
$0.63
+2.82%
(+0.017) 1D
$0.70
+10.94% (+0.069)
After hours
Closed: Nov 20, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LAB...
Open
$0.63
High
$0.65
Low
$0.57
Mkt. cap
249.11M
Avg. vol.
900.81K
Volume
2.81M
52-wk high
$1.72
52-wk low
$0.39
Beta
1.52
Shares outstanding
394.79M
No. of employees
387
Open
$0.63
High
$0.65
Low
$0.57
Mkt. cap
249.11M
Avg. vol.
900.81K
Volume
2.81M
52-wk high
$1.72
52-wk low
$0.39
Beta
1.52
Shares outstanding
394.79M
No. of employees
387
News stories
From web sources and news partners
Profile
Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits, and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications. Standard BioTools sells products to academic research institutions; translational research and medical centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology and plant and animal research companies; and contract research organizations. Wikipedia
About Standard Biotools Inc
CEO-
Employees387
Founded1999
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
Industry-
Analyst
Recommendation
Action
Price target
Projected
Date
Kyle Boucher
TD Cowen
Hold
Maintained
$1.35
+113.9%
05/05/2026
Paul Knight
KeyBanc
Hold
Maintained
-
-
02/25/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
$0.03 / -$0.01
+400.00%beat
Revenue / Est. (USD)
19.38M / 18.80M
+3.11%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
23.80M
21.15M
20.10M
19.38M
Cost of goods sold
12.41M
11.79M
9.57M
8.56M
Cost of revenue
12.41M
11.79M
9.57M
8.56M
Research and development expenses
7.97M
162.00K
1.98M
2.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.34M
18.61M
16.39M
16.84M
Operating expense
33.31M
18.77M
18.36M
18.92M
Total operating expenses
45.72M
30.56M
27.93M
27.48M
Operating income
-21.92M
-9.42M
-7.83M
-8.09M
Other non operating income
4.96M
-2.14M
-658.00K
-64.00K
EBT including unusual items
-22.03M
-14.62M
-21.44M
-14.95M
EBT excluding unusual items
-15.31M
-8.04M
-3.88M
-3.28M
Income tax expense
-35.93M
11.00K
90.00K
27.00K
Effective tax rate
163.10%
-0.08%
-0.42%
-0.18%
Other operating expenses
-
-
-
-
Net income
19.28M
127.07M
-26.76M
13.48M
Net profit margin
81.04%
600.91%
-133.10%
69.55%
Earnings per share
0.07
-0.02
-
-
Interest and investment income
1.66M
3.51M
4.61M
4.88M
Interest expense
-5.00K
-
-
-
Net interest expenses
1.66M
3.51M
4.61M
4.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.64M
-8.01M
-6.56M
-6.89M
Gain or loss from assets sale
-
-
-172.29M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps